Navigation Links
FDA, NIH to Speak at CBI's 14th Annual Registries and Post-Approval Studies Congress

WOBURN, Mass., Aug. 18, 2011 /PRNewswire/ -- CBI is pleased to announce the full agenda for its industry-leading, 14th Annual Registries and Post-Approval Studies Congress, being held September 20-22, 2011 in Philadelphia, PA. The program, sponsored by REGISTRAT-MAPI, boasts an impressive speaker lineup from Celgene, Covidien, FDA, Forest, Ironwood Pharmaceuticals, Merck, NIH, Pfizer, Takeda Europe and many more.

Attendees have the opportunity to customize their congress experience by choosing between breakout sessions, concurrent tracks and participating in interactive panel discussions. Session highlights include:

  • Driving Value in Research by Designing, Implementing and Improving Patient Registries
  • Optimizing Post-Marketing Requirements and REMS
  • Developing Strategies to Benefit Sponsor and Regulatory Authorities
  • Complying with U.S., EU and Canadian Post-Approval Requirements
  • Responding to Increased Payer Requirements to Support Reimbursement Decisions
  • Maximizing the Value of Registries and Other Post-Approval Studies

Industry leaders will be afforded the exclusive opportunity to participate in the Invitation-Only Post-Approval Executive Summit hosted by REGISTRAT-MAPI. This 5th Annual Summit provides a unique forum for senior-level executives involved in post-approval studies, including clinical, medical, safety and regulatory to address the strategic issues they face.

CBI's Post-Approval Studies series is the industry's premier source for cutting-edge content and unparalleled programming related to post-approval studies. For more information on the conference or to view the entire agenda, please visit

About CBI:

CBI, a subsidiary of Advanstar, is the leading provider of market-driven, unbiased conferences for the pharmaceutical, biotechnology, medical device and healthcare industries. CBI offers specialized information presented in interactive formats by thought leaders and regulators. For more information, please visit

About REGISTRAT-MAPI, Global Foundation Sponsor:

REGISTRAT-MAPI provides strategic and operational solutions for our clients in the design and implementation of Late Phase studies. REGISTRAT-MAPI is the pharmaceutical industry's largest global CRO dedicated exclusively to real-world clinical research. With more than 250 experienced professionals, REGISTRAT-MAPI has served the pharmaceutical and medical device industries for more than 20 years. For more information, please visit

For additional information or media inquiries, please contact Emily Forest, CBI Marketing Manager, at 339-298-2156 or Amy Wynn, REGISTRAT-MAPI Manager, Global Marketing, at 215-568-0121.

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Accuray Incorporated to Speak at 2011 Wedbush Life Sciences: Management Access Conference
2. Pathogenica CSO Speaks at IBC Life Sciences Drug Discovery & Diagnostic Development Week
3. Qteros Management to Speak at June Conferences
4. CBI Keynote Speakers on Cover of Time Magazine
5. Verenium to Speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing
6. Pam Marrone to Speak at Ag 2.0 Conference
7. Pharma ChemOutsourcing 2011 Unveils First Wave of 50 Biotech Chemist Speakers for September 12-15 Show in New Jersey
8. Science advisor to the US EPA to speak to industry, academic leaders on sustainability innovations
9. PRA International Expert to Speak at China Drug Safety Summit
10. Tianyins Dr. James Jiayuan Tong is Invited to Speak at the CFO China Summit 2011 on January 19, 2011 at the St. Regis Hotel, Beijing
11. Accuray Incorporated to Speak at Seventh Annual Lazard Capital Markets Healthcare Conference
Post Your Comments:
(Date:11/28/2015)... ... ... • Jeon Jin Bio Corp, a Korean Biotech venture company, has developed ... Bird Free, an oil-based, gel formula made from natural ... smell, taste and touch, enabling safe, effective avian control without toxic chemicals , ...
(Date:11/26/2015)... 26, 2015 --> ... in imaging technologies, announced today that it has received a ... the Horizon 2020 European Union Framework Programme for Research and ... trial in breast cancer. , --> ... --> --> The study aims to ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 /PRNewswire/ ... ), a biotechnology company developing bioengineered organ implants for ... will present at the LD Micro "Main Event" ... p.m. PT. The presentation will be webcast live and ... will also be available at the conference for one-on-one ...
(Date:11/25/2015)... November 25, 2015 The ... is a professional and in-depth study on the ...      (Logo: ) , ... industry including definitions, classifications, applications and industry chain ... the international markets including development trends, competitive landscape ...
Breaking Biology Technology:
(Date:11/16/2015)... Calif. , Nov 16, 2015  Synaptics ... of human interface solutions, today announced expansion of ... TouchView ™ touch controller and display driver ... revolution of smartphones. These new TDDI products add ... TD4100 (HD resolution), TD4302 (WQHD resolution), and TD4322 ...
(Date:11/10/2015)... Nov. 10, 2015  In this report, ... basis of product, type, application, disease indication, ... this report are consumables, services, software. The ... safety biomarkers, efficacy biomarkers, and validation biomarkers. ... are diagnostics development, drug discovery and development, ...
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
Breaking Biology News(10 mins):